EVPL

EVPL (envoplakin) is a plakin family cytolinker protein that serves as a membrane-associated precursor of the epidermal cornified envelope, linking desmosomes and keratin intermediate filaments in stratified epithelia (PMID:8938451). Its transcription is directly activated by p63 through a specific response element (RRRCGTGYYY) in the EVPL promoter, with BRD4 acting as a co-activator of p63-dependent EVPL expression in keratinocytes (PMID:15988020, PMID:39605045). EVPL functions as a tumor suppressor by inhibiting the RAS/RAF/ERK signaling pathway, suppressing cancer cell proliferation, migration, invasion, and macrophage M2 polarization; its loss also confers radioresistance and modulates NF-κB/TNF-dependent immune gene expression in esophageal squamous cell carcinoma (PMID:38504693, PMID:33633453, PMID:41905574). EVPL is a major autoantigen in paraneoplastic pemphigus, with dominant B-cell epitopes mapped to its N-terminal domain (aa 1–141) and linker subdomain (aa 1684–1784) (PMID:27427435).

1. 1996 Medium

   Identification of EVPL as a plakin family member and cornified envelope precursor established its structural kinship with desmoplakin, BPAG1, and plectin, suggesting a cytolinker function bridging desmosomes to keratin filaments.

   Evidence Somatic cell hybrid/FISH mapping to 17q25 and sequence homology analysis

   PMID:8938451

   Open questions at the time

   • Functional cytolinker role inferred from homology, not directly demonstrated
   • No direct interaction data with desmosomal or intermediate filament proteins
2. 2005 High

   Discovery that p63 directly transactivates EVPL through a non-canonical response element resolved how EVPL expression is restricted to stratified epithelia and connected it to the master epithelial transcription factor p63.

   Evidence EMSA, luciferase reporter mutagenesis, and loss of EVPL protein in p63-knockout mouse skin

   PMID:15988020

   Open questions at the time

   • Whether other transcription factors cooperate with p63 at the EVPL promoter was unknown at this stage
   • Post-transcriptional regulation of EVPL unexplored
3. 2016 Medium

   Systematic epitope mapping of EVPL in paraneoplastic pemphigus defined two dominant autoantibody-binding regions, linking specific EVPL structural domains to autoimmune pathology.

   Evidence ELISA with 12 overlapping recombinant EVPL fragments tested against 65 PNP patient sera

   PMID:27427435

   Open questions at the time

   • Whether autoantibodies are pathogenic (causing tissue damage) versus epiphenomenal not established
   • Structural basis of epitope immunodominance unknown
4. 2021 Medium

   Demonstrating that EVPL knockdown increases radioresistance and alters NF-κB/TNF-dependent cytokine expression first connected EVPL to immune signaling and treatment response in cancer.

   Evidence RNAi knockdown in ESCC cells with clonogenic survival assays and RNA-seq

   PMID:33633453

   Open questions at the time

   • Mechanism by which EVPL modulates NF-κB/TNF signaling not defined
   • In vivo validation of radioresistance phenotype absent
   • Single cell line tested
5. 2024 Medium

   Placing EVPL upstream of RAS/RAF/ERK signaling in melanoma, with rescue and inhibitor experiments, established EVPL as a tumor suppressor that restrains ERK-driven proliferation, invasion, and macrophage polarization.

   Evidence EVPL overexpression/knockdown in melanoma cells with ERK inhibitor rescue, co-culture Transwell, Western blot for pathway components

   PMID:38504693

   Open questions at the time

   • Direct molecular target through which EVPL inhibits RAS/ERK not identified
   • In vivo tumor suppressor activity not demonstrated
   • Whether EVPL acts at the membrane, cytosol, or both in this context is unclear
6. 2024 Medium

   Identification of BRD4 as a p63 co-activator at the EVPL locus refined the transcriptional regulatory mechanism and linked epigenetic reader activity to EVPL-dependent keratinocyte differentiation.

   Evidence BRD4–p63 co-immunoprecipitation, ChIP at EVPL locus, JQ1 inhibitor and knockdown experiments in keratinocytes

   PMID:39605045

   Open questions at the time

   • Whether BRD4 is required specifically at the EVPL locus versus broadly for p63 target genes not distinguished
   • Functional consequence of BRD4-mediated EVPL regulation on cornified envelope assembly not tested
7. 2026 Medium

   Discovery of the AGTPBP1/EVPL/ERK axis in breast cancer provided an upstream repressor of EVPL and reinforced the generality of the EVPL–ERK tumor suppressor mechanism across cancer types.

   Evidence RNA-seq, AGTPBP1 overexpression/knockdown with EVPL rescue, Western blot for p-ERK1/2 in breast cancer cells

   PMID:41905574

   Open questions at the time

   • Mechanism by which AGTPBP1 (a carboxypeptidase) represses EVPL expression is unknown
   • Whether EVPL directly binds a RAS/ERK pathway component remains unresolved
   • In vivo validation of this axis absent

• The direct molecular mechanism by which EVPL suppresses RAS/ERK signaling — whether through protein–protein interaction, scaffolding, or indirect effects — remains unknown, as does EVPL's precise structural role in cornified envelope assembly beyond homology-based inference.
• No binding partner or direct target in the RAS/ERK pathway identified for EVPL
• Structural/biochemical reconstitution of EVPL in cornified envelope assembly not performed
• In vivo tumor suppressor function of EVPL not demonstrated in animal models